S&P 500 Futures
(-1.20%) 5 046.00 points
Dow Jones Futures
(-1.13%) 38 243 points
Nasdaq Futures
(-1.57%) 17 387 points
Oil
(0.22%) $82.99
Gas
(-1.09%) $1.635
Gold
(0.15%) $2 341.90
Silver
(0.75%) $27.55
Platinum
(-0.33%) $912.80
USD/EUR
(0.14%) $0.936
USD/NOK
(0.25%) $11.01
USD/GBP
(-0.05%) $0.802
USD/RUB
(-0.64%) $91.73

Realtime updates for Pharnext SA [ALPHA.PA]

Exchange: EURONEXT Industry: Biotechnology
Last Updated25 Apr 2024 @ 08:41

-1.43% 0.138

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 08:41):

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis...

Stats
Today's Volume 279 880
Average Volume 23 031.00
Market Cap 30 173.00
EPS €0 ( 2024-04-19 )
Last Dividend €0 ( N/A )
Next Dividend €0 ( N/A )
P/E 0
ATR14 €0.00600 (4.35%)

Pharnext SA Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharnext SA Financials

Annual 2022
Revenue: €558.00
Gross Profit: €2.26M (404 643.19 %)
EPS: €-8.32
Q2 2023
Revenue: €150 000
Gross Profit: €763 025 (508.68 %)
EPS: €-69 969 278
Q4 2022
Revenue: €1.06M
Gross Profit: €689 450 (65.22 %)
EPS: €-26.27
Q2 2022
Revenue: €558.00
Gross Profit: €1.20M (215 193.01 %)
EPS: €-222 250 000 000 000

Financial Reports:

No articles found.

Pharnext SA

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators